To analyse the humoral immune response to SARS-CoV-2 following vaccination in treated patients with multiple sclerosis.
Latest Information Update: 05 Apr 2022
At a glance
- Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 05 Apr 2022 New trial record
- 26 Feb 2022 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022